Patient-Centered Management of CDK4/6 Inhibitor Therapy: Adverse Event Mitigation, Adherence, and Persistence in HR+/HER2- Breast Cancer

In this episode, Danielle Roman, PharmD, BCOP, and Jordan Hill, PharmD, BCOP, discuss patient-centered management of CDK4/6 inhibitor therapy in HR-positive/HER2-negative breast cancer, with a focus on how oncology pharmacists and the multidisciplinary care team can support patients through treatment, including: Practical strategies for monitoring and managing key adverse events associated with abemaciclib, ribociclib, and palbociclib, such as diarrhea, neutropenia, hepatotoxicity, and QT prolongation How dose interruptions and dose reductions can help improve tolerability while maintaining clinical benefit Real-world approaches to patient education, toxicity counseling, and communication that can improve adherence and persistence with oral CDK4/6 inhibitor therapy Additional considerations such as financial toxicity, coordination with specialty pharmacy, and practical tools to help patients stay on therapy over the long term  Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Danielle Roman, PharmD, BCOP Manager, Oncology Clinical Pharmacy Services Oncology Clinical Pharmacy Specialist Allegheny Health Network Pittsburgh, Pennsylvania Jordan Hill, PharmD, BCOP Clinical Pharmacy Specialist, Breast Oncology West Virginia University Cancer Institute Morgantown, West Virginia Link to full program:https://bit.ly/4cIYca6 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.